Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Pan-cancer DMR cfDNA methylation model (PMID 42028006)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pan-cancer conserved DMR framing is a meaningful advance over single-cancer methylation markers; approach of identifying cross-cancer conserved methylation signatures rather than tumor-specific panels is genuinely novel, though cfDNA methylation liquid biopsy is an active field |
| Clinical Relevance | 8 | 77% sensitivity / 96.9% specificity across 7 cancer types with stage I/II sensitivity >69% — directly addresses the core challenge of multi-cancer early detection; clinically meaningful false-positive rate |
| Population Reach | 9 | Multi-cancer screening could benefit the entire adult population eligible for cancer screening globally; 7 cancer types covered represent enormous disease burden |
| Implementation Speed | 5 | Requires prospective validation, regulatory approval (IVD pathway), laboratory infrastructure for cfDNA methylation sequencing; realistically 3–6 years to broad clinical use |
| Evidence Strength | 7 | Retrospective observational cohort, n=1,108, multi-cancer design with training/validation split; PMC full text available; limitations include retrospective design, hospital-based population (not population screening context), and 11→7 cancer type reduction in validation |
Key quantitative result: 77% sensitivity, 96.9% specificity; stage I sensitivity 69.6%, stage II 70.4% External validation: Internal train/validate split; not yet independently replicated by separate group Main limitation: Retrospective, hospital-based cohort — sensitivity/specificity may not generalize to asymptomatic population-level screening where pre-test probability is much lower and true PPV will decline Equity implications: A low-cost, non-invasive pan-cancer test could democratize screening in LMICs, but methylation sequencing infrastructure is currently concentrated in high-income settings Evidence Maturity: Validated (confirm) — appropriate for retrospective multi-cancer cohort; prospective population study needed before practice-changing designation
Article 2 — Oncolytic viruses and cytokine gene therapies TME review (PMID 42032342)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Synthesizes a rapidly moving field with clinical trial data; no new primary findings but consolidates translational gaps usefully in Nature Cancer |
| Clinical Relevance | 6 | Directly relevant to oncology practice but as a review synthesizing existing knowledge rather than generating new evidence; highlights durable response gaps |
| Population Reach | 7 | Solid tumors represent the majority of cancer burden globally; TME reprogramming strategies cut across many cancer types |
| Implementation Speed | 4 | Several agents already approved; but durable responses remain elusive — review itself acknowledges translational gaps. Combination strategies are early-stage |
| Evidence Strength | 5 | Review design; abstract only; no primary data generated. Nature Cancer venue adds credibility but cannot overcome design limitation |
Key quantitative result: Qualitative synthesis; no single primary effect size External validation: Review of published trials — no new validation Main limitation: Review articles cannot be scored on evidentiary rigor the same as primary studies; abstract-only access limits assessment of evidence selection methodology Equity implications: Oncolytic virus and gene therapies are among the most expensive and infrastructure-intensive therapeutics; access will be heavily skewed toward high-income settings Evidence Maturity: Validated (confirm for synthesized field knowledge) — individual trials reviewed are validated; overall therapeutic strategy remains incompletely proven
Article 3 — CRISPR/Cas12a ctDNA detection for breast cancer (PMID 42027134)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | CRISPR/Cas12a + GCRCA nanomaterial platform for attomolar ctDNA detection with single-base discrimination is technically innovative; grape-cluster rolling circle amplification is a novel construct |
| Clinical Relevance | 5 | AUC 0.978 and 100% specificity in 42 samples are impressive but n=42 severely limits clinical interpretation; single mutation (PIK3CA E542K) coverage constrains utility |
| Population Reach | 6 | Breast cancer is the most common cancer in women globally; PIK3CA mutations are present in ~35% of breast cancers — substantial target population if validated |
| Implementation Speed | 3 | Preclinical/early validation stage; requires large-scale clinical validation, regulatory approval, manufacturing scale-up, and cost reduction |
| Evidence Strength | 4 | Small n=42 clinical cohort; abstract only; single-center; classification confidence medium — cannot draw strong clinical conclusions |
Key quantitative result: AUC 0.978, 100% specificity, attomolar sensitivity, 30-min assay time External validation: None reported; single-center validation cohort only Main limitation: n=42 is wholly inadequate for clinical validation of a diagnostic test; PIK3CA E542K is one of several PIK3CA hotspot mutations Equity implications: Rapid, potentially low-cost CRISPR-based assay could theoretically be more accessible than NGS-based liquid biopsy if manufacturing costs are controlled Evidence Maturity: Exploratory (confirm) — technically promising, clinically premature
Article 4 — Deep learning for pituitary neuroendocrine tumor histology (PMID 42031964)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First well-validated DL model for PitNET lineage classification from routine H&E with spatial transcriptomic recurrence biology integration; addresses a real diagnostic gap |
| Clinical Relevance | 7 | Pituitary tumor subtype classification has direct implications for surgical planning, adjuvant therapy, and surveillance frequency; high-risk subtype prediction (AUC 0.733–0.805) is immediately clinically useful |
| Population Reach | 4 | Pituitary tumors are relatively uncommon (~1–2 per 100,000/year); however, within this rare disease context, unmet diagnostic need is high — graded relative to affected population |
| Implementation Speed | 6 | H&E slides are universally available; DL model deployment requires digital pathology infrastructure but this is increasingly standard at academic centers; two-center external validation strengthens near-term adoption argument |
| Evidence Strength | 8 | Strong: n=1,344 total with two independent external validation cohorts (Taihe n=226, Huashan n=193); multicenter design; NPJ Precision Oncology; abstract only is the limitation |
Key quantitative result: AUC 0.912 lineage classification; 0.805/0.753/0.733 high-risk subtype AUCs; external validation in 419 patients External validation: Yes — two independent external cohorts Main limitation: Abstract only reviewed; spatial transcriptomic mechanistic data likely limited to discovery cohort; clinical outcome data (recurrence, survival) needs prospective follow-up Equity implications: Benefit concentrated at centers with digital pathology infrastructure; may reduce variability in PitNET diagnosis between specialized and non-specialized centers if deployed broadly Evidence Maturity: Validated (confirm)
Article 5 — AML leukemic stem cell niche localization (PMID 42032313)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Three-scale spatial mapping of LSC niches in AML bone marrow with identification of a DPP4-CXCL12-GPC3 axis is a landmark mechanistic contribution; genuinely new spatial framework |
| Clinical Relevance | 4 | Non-human study cap applies (≤5); DPP4 inhibitors are clinically available (gliptins) creating translational angle, but human validation is absent |
| Population Reach | 6 | AML affects ~20,000 new patients/year in the US alone; LSC-mediated relapse is the primary cause of treatment failure — high unmet need relative to disease population |
| Implementation Speed | 3 | Lab stage; human validation, clinical trial design, and regulatory pathway needed; DPP4 inhibitor repurposing could accelerate timeline but remains speculative |
| Evidence Strength | 4 | Preclinical mouse model only; no human validation; abstract only. High rigor within animal model paradigm but non-human cap applies |
Key quantitative result: DPP4 targeting disrupts CXCL12 gradient and displaces LSCs; specific quantitative effect sizes not available from abstract External validation: None in humans Main limitation: Mouse model; whether spatial niche dynamics are conserved in human AML bone marrow architecture requires direct validation Equity implications: Premature to assess; if DPP4 inhibitor repurposing succeeds, these drugs are widely available and low-cost Evidence Maturity: Exploratory (confirm)
Article 6 — MDS/MPN overlap allo-HCT registry analysis (PMID 42032308)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Clinically important confirmation but not conceptually surprising; MDS/MPN overlap biology is known to be more aggressive; this quantifies the transplant outcome gap |
| Clinical Relevance | 7 | Directly informs transplant decision-making, conditioning intensity selection, and post-transplant maintenance strategy for a poorly-studied entity |
| Population Reach | 3 | MDS/MPN overlap (CMML, MDS/MPN-U, RARS-T) is rare; but within affected patients undergoing HCT, impact is high — scored relative to relevant clinical population |
| Implementation Speed | 7 | Registry-based observational data; no new intervention required; finding can immediately inform pre-transplant counseling and protocol design at transplant centers |
| Evidence Strength | 5 | Registry design (SBTMO/CIBMTR) provides real-world validity; however, sample size not retrieved, abstract only, classification confidence medium; retrospective with potential confounders |
Key quantitative result: Significantly higher relapse rates post-allo-HCT in MDS/MPN vs. MDS (specific OR/HR not available from abstract) External validation: Multi-center registry (CIBMTR) provides broad population representation Main limitation: Sample size unknown from available data; retrospective registry with potential selection bias; abstract only Equity implications: Brazilian population data — adds important Latin American representation to a field dominated by European/North American registries; 🟡 relevant to underserved populations Evidence Maturity: Validated (confirm for registry-level observational evidence)
Article 7 — Nocturnal hypertension in pregnancy WCH (PMID 42032277)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Challenges the established "benign" classification of WCH in pregnancy specifically via nocturnal BP subgroup; not entirely novel concept but well-executed and clinically impactful framing |
| Clinical Relevance | 8 | Directly actionable: preeclampsia OR 11.95 in WCH+nocturnal HTN subgroup comparable to sustained HTN — a single finding that could change ABPM protocols in obstetric care |
| Population Reach | 7 | WCH is common (~15–30% of hypertensive pregnancies); preeclampsia affects ~2–8% of all pregnancies globally; implementation would affect millions of pregnant women annually |
| Implementation Speed | 7 | ABPM is already available at most obstetric centers; adding nocturnal BP assessment requires no new technology, just protocol adjustment; near-term implementable |
| Evidence Strength | 6 | Retrospective cohort n=991; large for this specific question; high-confidence classification; limited by retrospective design and single country (Argentina) setting |
Key quantitative result: OR 11.95 (p=0.018) for preeclampsia in WCH+nocturnal HTN vs. normotensive; comparable to sustained HTN External validation: None reported; single-country cohort Main limitation: Retrospective, single-country; generalizability to different obstetric populations and healthcare systems uncertain; abstract only Equity implications: ABPM devices are more accessible than advanced genomic tools; implementation in LMICs requires device availability and trained personnel — still a meaningful barrier Evidence Maturity: Validated (confirm) — sufficient for protocol consideration pending prospective replication
Article 8 — DeepDrugDiscovery for Alzheimer's autophagy enhancers (PMID 42032039)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Mechanism-aware AI platform integrating ADMET + BBB permeability with mTOR-independent autophagy targeting is a conceptually fresh approach to AD drug discovery; open-source release adds field-wide value |
| Clinical Relevance | 4 | Non-human study (≤5 cap); AD has massive unmet need but preclinical-to-clinical translation rate in AD is historically very poor; scored conservatively |
| Population Reach | 9 | Alzheimer's disease affects ~55 million people globally; any credible new therapeutic approach has enormous potential reach |
| Implementation Speed | 2 | Lab stage only; IND-enabling studies, Phase I/II/III trials needed; AD drug development timeline typically 10–15 years |
| Evidence Strength | 4 | Cross-species validation (C. elegans + mouse) strengthens preclinical confidence; but non-human cap, abstract only, no human data |
Key quantitative result: BBB penetration confirmed; Aβ/tau aggregate clearance and memory restoration in mouse models (specific effect sizes not available from abstract) External validation: Cross-species (worm + mouse) provides limited orthogonal validation; no human or primate data Main limitation: Catastrophic preclinical-to-clinical attrition in AD drug development; mTOR-independent autophagy enhancement has not been validated in humans Equity implications: Open-source platform could enable drug discovery in resource-limited settings and academic groups; democratizing potential if platform is truly accessible Evidence Maturity: Exploratory (confirm)
Article 9 — RPS4X variants cause X-linked intellectual disability (PMID 42031741)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel XLID gene discovery with functional validation; ribosomal protein involvement in XLID is not unprecedented but RPS4X is genuinely new; multi-cohort confirmation including 100,000 Genomes Project adds credibility |
| Clinical Relevance | 6 | Within the rare disease context: diagnostic yield improvement for undiagnosed XLID patients is high-value; enables genetic counseling, family planning, and potential future targeted therapy |
| Population Reach | 3 | Very rare; X-linked intellectual disability broadly affects ~1–3/10,000 males, but RPS4X-specific syndrome is ultra-rare. Scored relative to XLID diagnostic landscape |
| Implementation Speed | 5 | Gene can be added to diagnostic panels immediately; functional understanding needed before treatment implications emerge |
| Evidence Strength | 6 | Mixed species; n=6 is appropriate for rare disease gene discovery (comparable to landmark XLID gene papers); functional validation in fibroblasts and zebrafish; multi-cohort identification strengthens causal inference |
Key quantitative result: 6 individuals confirmed; pathogenic missense variants in RPS4X; functional rescue data in zebrafish (specific effect sizes not available from abstract) External validation: Multi-cohort identification (including 100,000 Genomes Project) serves as orthogonal validation Main limitation: Extremely small n; zebrafish model may not fully recapitulate human neurodevelopmental pathology; no treatment data Equity implications: Rare disease gene discovery benefits families worldwide but access to genomic diagnosis via 100,000 Genomes-type programs remains limited to high-income countries; 🟡 underserved rare disease population Evidence Maturity: Exploratory (confirm) — foundational gene discovery, not yet therapeutically actionable
Article 10 — ML prediction of postoperative depression in ovarian cancer (PMID 42023444)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | ML depression prediction models are common; ovarian cancer surgical context is more specific but not groundbreaking; 13-variable random forest is methodologically standard |
| Clinical Relevance | 6 | Postoperative depression in cancer patients is underrecognized and undertreated; a validated 13-variable clinical tool could enable targeted mental health referrals in a high-burden population |
| Population Reach | 5 | Ovarian cancer has ~320,000 new cases/year globally; 31.5% postop depression prevalence creates substantial addressable burden |
| Implementation Speed | 6 | Variables (CA125, opioid use, prior depression) are routinely collected; model could be implemented as a clinical calculator with limited IT infrastructure |
| Evidence Strength | 6 | n=850 with internal validation; AUC 0.776 is modest but acceptable for psychiatric risk prediction; retrospective single-center design limits generalizability |
Key quantitative result: AUC 0.776, Brier score 0.182, sensitivity 0.771; 31.5% depression prevalence in cohort External validation: Internal validation only; no external cohort Main limitation: Single-center retrospective; no external validation; AUC 0.776 leaves meaningful classification uncertainty; depression diagnosis methodology not specified Equity implications: Mental health in oncology is globally underserved; a simple clinical calculator could benefit patients at centers without specialist psychiatric services Evidence Maturity: Validated (confirm for model development stage; external validation needed before clinical deployment)
Article 11 — T cell senescence and organ aging review (PMID 42032757)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesizes NR4a network and T cell immunosenescence in organ aging; some novel mechanistic framing but review format limits novelty scoring |
| Clinical Relevance | 4 | Early-stage clinical interventions highlighted but mostly preclinical; PD-1 blockade in aging context is genuinely interesting but not established practice |
| Population Reach | 8 | Aging affects all humans; T cell immunosenescence is universal; if interventions prove effective, population reach would be enormous |
| Implementation Speed | 3 | Interventions are preclinical or early-phase; senolytic CAR-T and mTOR inhibition for aging are years from clinical deployment |
| Evidence Strength | 3 | Review only; mixed species; abstract only; Exploratory designation appropriate |
Key quantitative result: No primary quantitative result (review) External validation: N/A Main limitation: Review design; cannot assess primary evidence quality from abstract alone Equity implications: Anti-aging interventions historically benefit wealthy populations disproportionately; access concerns are real Evidence Maturity: Exploratory (confirm)
Article 12 — Metal-isotopic suspension array for liquid biopsy (PMID 42027143)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | 135-channel mass cytometric barcoding is technically impressive; advance over optical limitations is genuine but this is a review of an evolving technology platform rather than primary validation |
| Clinical Relevance | 3 | Technology review without clinical outcome data; highly speculative clinical impact at this stage |
| Population Reach | 6 | If validated for cancer liquid biopsy, technology could benefit broad populations; currently infrastructure-intensive |
| Implementation Speed | 2 | ICP-MS mass cytometry is expensive, requires specialized infrastructure; not near-term deployable in standard clinical labs |
| Evidence Strength | 3 | Review article; no primary clinical data; abstract only |
Key quantitative result: Up to 135 mass channels; >60 simultaneous analytes without spectral crosstalk External validation: N/A (technology review) Main limitation: No clinical validation data presented; cost and infrastructure barriers are very high Equity implications: High-cost, high-infrastructure technology unlikely to benefit lower-resource settings in near term Evidence Maturity: Exploratory (confirm)
Article 13 — Multiple myeloma genomics review (PMID 42027619)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Comprehensive but not novel; landscape review of established MM genomics knowledge |
| Clinical Relevance | 4 | Useful reference; MRD monitoring by liquid biopsy section has direct clinical relevance but no new findings |
| Population Reach | 5 | Multiple myeloma: ~176,000 new cases/year globally; relevant disease burden |
| Implementation Speed | 4 | Describes implemented practices (NGS panels) and emerging ones (liquid biopsy MRD) |
| Evidence Strength | 3 | Review; no primary data; PMC full text available |
Key quantitative result: No primary result Evidence Maturity: Exploratory (confirm — review of existing landscape)
Article 14 — DL coronary artery calcium score from chest CT predicts CKD progression (PMID 42032494)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Opportunistic DL CAC scoring from non-gated CT is established; CKD progression endpoint is somewhat novel but incremental |
| Clinical Relevance | 5 | Cardiorenal risk stratification from existing scans is clinically useful; moderate impact given available cardiorenal risk tools |
| Population Reach | 6 | CKD affects ~13% of the global population; chest CT is widely performed; opportunistic risk scoring could reach large numbers |
| Implementation Speed | 5 | DL CAC tools are commercially available; integration into CKD monitoring pathways requires workflow changes but is feasible |
| Evidence Strength | 4 | Retrospective; sample size unknown; abstract only; medium confidence classification |
Key quantitative result: DL CAC associated with CKD progression (specific HR/OR not available) Evidence Maturity: Exploratory (confirm)
Article 15 — Self-care experiences in elderly solitary heart failure patients (PMID 42032540)
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Qualitative thematic analysis of known psychosocial challenges; limited conceptual novelty |
| Clinical Relevance | 4 | Identifies actionable targets for discharge planning; limited by qualitative design and single-center, single-country context |
| Population Reach | 5 | Elderly HF patients living alone are a large and growing population globally |
| Implementation Speed | 5 | Qualitative findings could inform discharge protocol design relatively quickly |
| Evidence Strength | 3 | n=26, qualitative, single-center, single-country; design appropriate for its purpose but lowest evidentiary tier |
Key quantitative result: 4 psychosocial themes (qualitative) Evidence Maturity: Exploratory (confirm)
PHASE 3 — Ranking
Conflict / Convergence Note
No direct conflicts across articles in this batch — they address largely distinct clinical questions. Articles 1 and 3 both relate to cfDNA/ctDNA liquid biopsy diagnostics but are complementary (pan-cancer methylation model vs. single-mutation CRISPR assay). Articles 7 (nocturnal hypertension in pregnancy) and 6 (MDS/MPN transplant outcomes) both demonstrate clinically actionable findings in underserved populations through different mechanisms. No articles present contradictory data.
Composite Impact Score Calculation
Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%
| # | Article (short link) | CR (30%) | PR (25%) | SN (20%) | IS (15%) | ES (10%) | Impact Score | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Pan-cancer DMR cfDNA | 8 | 9 | 7 | 5 | 7 | 7.55 | 8 | 🔴 |
| 7 | Nocturnal HTN pregnancy | 8 | 7 | 6 | 7 | 6 | 7.15 | 6 | 🟢 |
| 4 | DL PitNET histology | 7 | 4 | 7 | 6 | 8 | 6.45 | 7 | 🟢 |
| 6 | MDS/MPN allo-HCT registry | 7 | 3 | 5 | 7 | 5 | 5.70 | 6 | 🟡 |
| 2 | Oncolytic virus TME review | 6 | 7 | 6 | 4 | 5 | 5.85 | 7 | ⬜ |
| 8 | DeepDrugDiscovery AD | 4 | 9 | 8 | 2 | 4 | 5.50 | 6 | ⚪ |
| 5 | AML LSC niche biology | 4 | 6 | 9 | 3 | 4 | 5.25 | 5 | ⚪ |
| 10 | ML postop depression OvCa | 6 | 5 | 4 | 6 | 6 | 5.45 | 5 | ⬜ |
| 9 | RPS4X XLID gene | 6 | 3 | 8 | 5 | 6 | 5.60 | 6 | 🟡 |
| 3 | CRISPR ctDNA breast cancer | 5 | 6 | 8 | 3 | 4 | 5.30 | 7 | ⚪ |
| 11 | T cell senescence review | 4 | 8 | 5 | 3 | 3 | 4.85 | 5 | ⬜ |
| 14 | DL CAC score CKD | 5 | 6 | 5 | 5 | 4 | 5.05 | 4 | ⬜ |
| 12 | Metal-isotopic barcoding | 3 | 6 | 6 | 2 | 3 | 4.10 | 5 | ⚪ |
| 13 | MM genomics review | 4 | 5 | 3 | 4 | 3 | 3.95 | 4 | ⬜ |
| 15 | HF self-care qualitative | 4 | 5 | 3 | 5 | 3 | 4.00 | 3 | ⬜ |
Final Ranked Table
| Rank | Article | Impact Score | CR | PR | SN | IS | ES | Triage | Design | Flag |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pan-cancer DMR cfDNA methylation model | 7.55 | 8 | 9 | 7 | 5 | 7 | 8 | Observational cohort (retrospective, n=1,108) | 🔴 |
| 2 | Nocturnal HTN reclassifies WCH pregnancy risk | 7.15 | 8 | 7 | 6 | 7 | 6 | 6 | Retrospective cohort (n=991) | 🟢 |
| 3 | DL PitNET lineage classification from H&E | 6.45 | 7 | 4 | 7 | 6 | 8 | 7 | DL model + 2 external validation cohorts (n=1,344) | 🟢 |
| 4 | Oncolytic virus TME reprogramming review | 5.85 | 6 | 7 | 6 | 4 | 5 | 7 | Review (Nature Cancer) | ⬜ |
| 5 | MDS/MPN allo-HCT outcomes registry | 5.70 | 7 | 3 | 5 | 7 | 5 | 6 | Registry observational (SBTMO/CIBMTR) | 🟡 |
| 6 | RPS4X XLID novel gene discovery | 5.60 | 6 | 3 | 8 | 5 | 6 | 6 | Genetic case series + functional validation (n=6) | 🟡 |
| 7 | DeepDrugDiscovery AD autophagy enhancers | 5.50 | 4 | 9 | 8 | 2 | 4 | 6 | AI platform + cross-species preclinical | ⚪ |
| 8 | ML postop depression ovarian cancer | 5.45 | 6 | 5 | 4 | 6 | 6 | 5 | Retrospective ML model (n=850) | ⬜ |
| 9 | AML LSC spatial niche biology | 5.25 | 4 | 6 | 9 | 3 | 4 | 5 | Preclinical mechanistic (mouse) | ⚪ |
| 10 | CRISPR/Cas12a ctDNA breast cancer | 5.30 | 5 | 6 | 8 | 3 | 4 | 7 | Diagnostic validation (n=42) | ⚪ |
| 11 | DL CAC score CKD progression | 5.05 | 5 | 6 | 5 | 5 | 4 | 4 | Retrospective cohort | ⬜ |
| 12 | T cell senescence and organ aging review | 4.85 | 4 | 8 | 5 | 3 | 3 | 5 | Review | ⬜ |
| 13 | Metal-isotopic suspension array review | 4.10 | 3 | 6 | 6 | 2 | 3 | 5 | Technology review | ⚪ |
| 14 | HF self-care qualitative study | 4.00 | 4 | 5 | 3 | 5 | 3 | 3 | Qualitative descriptive (n=26) | ⬜ |
| 15 | Multiple myeloma genomics review | 3.95 | 4 | 5 | 3 | 4 | 3 | 4 | Review | ⬜ |
Rank 1 Justification: Pan-cancer DMR cfDNA earns the top rank by combining the largest clinical validation cohort in the batch (n=1,108), a technically novel pan-cancer DMR framing that advances the liquid biopsy field, and the highest Population Reach score (9/10) — multi-cancer early detection affects essentially the entire adult screening-eligible population globally. An Evidence Strength of 7 clears the minimum threshold for #1 ranking. The 96.9% specificity and >69% early-stage sensitivity represent clinically meaningful performance benchmarks that move this beyond proof-of-concept into actionable validation territory.
Why it matters: A single blood test that can detect seven cancer types with high specificity and meaningful early-stage sensitivity could fundamentally shift cancer screening from organ-specific programs to a universal blood-based annual test — reducing late-stage diagnoses across the most common malignancies simultaneously.
Rank 2 Justification: Nocturnal hypertension in WCH pregnancy ranks second on the strength of its immediate clinical actionability — OR 11.95 for preeclampsia is a clinically significant finding requiring no new technology, just a protocol change to include nocturnal ABPM. High Implementation Speed (7/10) and Clinical Relevance (8/10) reflect that this finding could be adopted at obstetric centers globally within months of guideline update, protecting millions of pregnant women from missed high-risk classification.
Rank 3 Justification: DL PitNET histology classification earns third place on the strength of its exceptional Evidence Strength (8/10) — the highest in the batch — with two independent external validation cohorts, multicenter design, and AUC 0.912 for lineage classification. While Population Reach is limited by disease rarity, the model directly addresses a genuine diagnostic gap in a specialty where subtype misclassification has real consequences for patient management.